Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.42 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256787 | 0.85 | ADORA2A (0.46) | AXLADORA2AADORA1KMOTGFBR1 | |
| SCHEMBL22529589 | 0.82 | PDK1 (0.50) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL12813116 | 0.80 | MAPK14 (0.42) | AXLADORA2AADORA1PDK1PDK2 | |
| SCHEMBL4540379 | 0.80 | ALDH1A1 (0.55) | MAPK1 | |
| SCHEMBL4753013 | 0.79 | ADORA2B (0.43) | ADORA2APDK1PDK2PDK3PDK4 | |
| SCHEMBL25551797 | 0.78 | KCNQ3 (0.42) | PDK1PDK2PDK3PDK4KMO | |
| SCHEMBL30036996 | 0.78 | KCNQ3 (0.42) | PDK1PDK2PDK3PDK4KMO | |
| SCHEMBL12813257 | 0.78 | AXL (0.47) | AXLADORA2AADORA1PDK1PDK2 | |
| SCHEMBL24852574 | 0.77 | PDK1 (0.48) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL31557673 | 0.77 | PDK1 (0.48) | PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628665-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | University of Utah Research Foundation (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-2693881-B1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | UNIV UTAH RES FOUND (US) | 2019-09-04 | — | — | EP | disclosed |
| US-8901120-B2 | Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2693881-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | University of Utah Research Foundation (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | SUMITOMO PHARMA ONCOLOGY, INC. | 2012-11-08 | — | — | US | disclosed |
| WO-2012135800-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | AXL, TYRO3, MERTK | AXL 1/4885ADORA2A 799/4885ADORA1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.